Dianthus Therapeutics, Inc. (DNTH)
NCM · Healthcare · Biotechnology
$106.20
+2.83%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$5.94B
Shares Outstanding
55.9M
P/S (TTM)
3,120x
Exchange
NCM
Currency
USD
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 396K | 284K | 463K | 761K |
| Operating Income | (40.3M) | (69.5M) | (46.5M) | (61.5M) |
| Net Income | (36.8M) | (64.4M) | (40.8M) | (50.2M) |
| Diluted EPS | $-0.97 | $-1.43 | $-0.85 | $-0.90 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 6.4M | 2.8M | 6.2M | 2.0M |
| Operating Income | (29.7M) | (48.2M) | (101.9M) | (177.9M) |
| Net Income | (28.5M) | (43.6M) | (85.0M) | (162.3M) |
| Diluted EPS | $-1.92 | $-8.45 | $-2.55 | N/A |